Advertisement

Pharmacy

Advertisement

Fluvoxamine, a drug that treats obsessive-compulsive disorder, could reduce the risk of respiratory deterioration and subsequent hospitalization in patients with early COVID-19, according to study results published Nov. 12 in the Journal of the American Medical Association.

Advertisement